BioSpace News Archive

JEOL Ltd. announces the release of the new electron microscope JEM-120i developed with the concepts of “Compact”, “Easy To Use”, and “Expandable” on May 30, 2024.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share.

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.

Anaveon, a clinical stage, immuno-oncology company, announced that its Investigational New Drug application to conduct a Phase I/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA.

Sedana Medical AB announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 2 phase III clinical trial in the United States.

JJP Biologics announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Application to conduct a phase I clinical study in healthy participants with their potential first-in-class anti-CD89 antagonist, JJP-1212.

Arrowhead Pharmaceuticals, Inc. announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran in patients with mixed hyperlipidemia.

West Pharmaceutical Services, Inc. announced that it will unveil its new Daikyo Crystal Zenith® Nested Vials in Tub at the International Society for Cell and Gene Therapy Annual Meeting taking place in Vancouver, Canada from May 29- June 1.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Application and granted Priority Review to inavolisib, an investigational oral therapy, in combination with palbociclib and fulvestrant.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, reported financial results for the three months ended March 31, 2024.